WO2018217064A3 - 형질전환된 t세포를 이용한 자연살해세포의 배양방법 - Google Patents

형질전환된 t세포를 이용한 자연살해세포의 배양방법 Download PDF

Info

Publication number
WO2018217064A3
WO2018217064A3 PCT/KR2018/005983 KR2018005983W WO2018217064A3 WO 2018217064 A3 WO2018217064 A3 WO 2018217064A3 KR 2018005983 W KR2018005983 W KR 2018005983W WO 2018217064 A3 WO2018217064 A3 WO 2018217064A3
Authority
WO
WIPO (PCT)
Prior art keywords
natural killer
transformed
cells
cell
culturing
Prior art date
Application number
PCT/KR2018/005983
Other languages
English (en)
French (fr)
Other versions
WO2018217064A2 (ko
Inventor
민보경
박경민
김현아
양빛나
황유경
김효진
Original Assignee
주식회사 녹십자랩셀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 녹십자랩셀 filed Critical 주식회사 녹십자랩셀
Priority to KR1020197030133A priority Critical patent/KR102460173B1/ko
Priority to EP18805231.0A priority patent/EP3633029A4/en
Priority to US16/613,601 priority patent/US20200108096A1/en
Priority to AU2018271755A priority patent/AU2018271755B2/en
Priority to CA3062130A priority patent/CA3062130A1/en
Priority to JP2019565241A priority patent/JP7039623B2/ja
Priority to CN201880034893.8A priority patent/CN110662834B/zh
Publication of WO2018217064A2 publication Critical patent/WO2018217064A2/ko
Publication of WO2018217064A3 publication Critical patent/WO2018217064A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 형질전환된 T세포를 이용한 자연살해세포의 배양방법에 관한 것이다. 본 발명의 형질전환된 T세포를 이용한 자연살해세포의 배양방법은 소량의 원료세포로부터 자연살해세포를 효과적으로 증식시켜 제조할 수 있다. 또한, 자연살해세포의 세포살해능도 향상시킨다. 따라서, 본 발명의 형질전환된 T세포를 이용한 자연살해세포의 배양방법은 세포치료제 상용화에 유용하게 사용될 수 있다. 나아가, 본 발명의 배양방법으로 제조된 자연살해세포는 세포치료제로서 유용하게 사용될 수 있다.
PCT/KR2018/005983 2017-05-26 2018-05-25 형질전환된 t세포를 이용한 자연살해세포의 배양방법 WO2018217064A2 (ko)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1020197030133A KR102460173B1 (ko) 2017-05-26 2018-05-25 형질전환된 t세포를 이용한 자연살해세포의 배양방법
EP18805231.0A EP3633029A4 (en) 2017-05-26 2018-05-25 PROCESS FOR CULTURING NATURAL KILLER CELLS USING A TRANSFORMED T LYMPHOCYTE
US16/613,601 US20200108096A1 (en) 2017-05-26 2018-05-25 Method for culturing natural killer cell, using transformed t cell
AU2018271755A AU2018271755B2 (en) 2017-05-26 2018-05-25 Method for culturing natural killer cell, using transformed T cell
CA3062130A CA3062130A1 (en) 2017-05-26 2018-05-25 Method for culturing natural killer cell, using transformed t cell
JP2019565241A JP7039623B2 (ja) 2017-05-26 2018-05-25 形質転換されたｔ細胞を用いてナチュラルキラー細胞を培養する方法
CN201880034893.8A CN110662834B (zh) 2017-05-26 2018-05-25 使用转化的t细胞培养自然杀伤细胞的方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0065180 2017-05-26
KR20170065180 2017-05-26

Publications (2)

Publication Number Publication Date
WO2018217064A2 WO2018217064A2 (ko) 2018-11-29
WO2018217064A3 true WO2018217064A3 (ko) 2019-03-28

Family

ID=64396946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/005983 WO2018217064A2 (ko) 2017-05-26 2018-05-25 형질전환된 t세포를 이용한 자연살해세포의 배양방법

Country Status (8)

Country Link
US (1) US20200108096A1 (ko)
EP (1) EP3633029A4 (ko)
JP (1) JP7039623B2 (ko)
KR (1) KR102460173B1 (ko)
CN (1) CN110662834B (ko)
AU (1) AU2018271755B2 (ko)
CA (1) CA3062130A1 (ko)
WO (1) WO2018217064A2 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN111757745B (zh) 2018-02-01 2022-11-04 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
CA3120085A1 (en) * 2018-11-14 2020-05-22 Green Cross Lab Cell Corporation Method for culturing cord blood-derived natural killer cells using transformed t-cells
CN111304255B (zh) * 2020-02-21 2023-06-09 中邦干细胞科技有限公司 一种滋养细胞、其制备方法及其在高效扩增nk细胞中的应用
EP4163366A1 (en) 2020-06-09 2023-04-12 Samsung Life Public Welfare Foundation Genetically-modified cell line for nk cell activation and amplification, and use thereof
CN112048482A (zh) * 2020-09-09 2020-12-08 广东昭泰体内生物医药科技有限公司 一种nk样细胞的培养方法
EP4262829A1 (en) * 2020-12-17 2023-10-25 Artiva Biotherapeutics, Inc. Expanded and stimulated natural killer cells
AU2022285433A1 (en) * 2021-06-01 2024-01-04 Kongju National University Industry-University Cooperation Foundation Composition containing feeder cell for proliferating natural killer cell
CN113599395B (zh) * 2021-09-22 2022-08-12 郑州源创吉因实业有限公司 含有nk细胞的治疗癌症的药物组合物
WO2023080895A1 (en) * 2021-11-04 2023-05-11 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and multispecific engagers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102911918A (zh) * 2011-12-29 2013-02-06 上海交通大学医学院 一种基因工程细胞及其在nk细胞扩增中的应用
JP5840837B2 (ja) * 2007-03-30 2016-01-06 メモリアル スローン−ケタリング キャンサー センター 養子移入ｔリンパ球における副刺激リガンドの構成性発現
CN106222141A (zh) * 2016-10-17 2016-12-14 湖南丰晖生物科技有限公司 Nk细胞培养液和细胞培养方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132283A2 (en) * 2008-04-24 2009-10-29 University Of Miami Method for treating autoimmune disorders
CN104204194B (zh) * 2011-12-22 2018-08-03 财团法人牧岩生命工学研究所 生产自然杀伤细胞的方法、由该方法生产的自然杀伤细胞以及包含该自然杀伤细胞的用于治疗癌症和感染性疾病的组合物
CN104321425B (zh) * 2012-05-07 2018-08-10 株式会社Nkmax 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法
CA2945305C (en) * 2014-04-10 2023-10-17 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method and compositions for cellular immunotherapy
CA2965952A1 (en) * 2014-10-27 2016-05-06 University Of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
KR101697473B1 (ko) * 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
GB201503500D0 (en) * 2015-03-02 2015-04-15 Ucl Business Plc Cell

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5840837B2 (ja) * 2007-03-30 2016-01-06 メモリアル スローン−ケタリング キャンサー センター 養子移入ｔリンパ球における副刺激リガンドの構成性発現
CN102911918A (zh) * 2011-12-29 2013-02-06 上海交通大学医学院 一种基因工程细胞及其在nk细胞扩增中的应用
CN106222141A (zh) * 2016-10-17 2016-12-14 湖南丰晖生物科技有限公司 Nk细胞培养液和细胞培养方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE NCBI 7 October 2008 (2008-10-07), "OX 40 ligand/ gp 34 [Homo sapiens]", XP055585825, Database accession no. CAA56284.1 *
DATABASE NCBI 8 June 2016 (2016-06-08), "TPA_inf: Homo sapiens mRNA for tumor necrosis factor ligand 5A (TNLG5A gene)", XP055585818, Database accession no. LN874322.1 *
LEE, JAE KWON ET AL.: "Development of NK Cell Expansion Methods Using Feeder Cells from Human Myelogenous Leukemia Cell Line", BLOOD RESEARCH, vol. 49, no. 3, 2014, pages 154 - 161, XP055585832 *

Also Published As

Publication number Publication date
AU2018271755B2 (en) 2021-12-23
JP7039623B2 (ja) 2022-03-22
CN110662834A (zh) 2020-01-07
US20200108096A1 (en) 2020-04-09
WO2018217064A2 (ko) 2018-11-29
CA3062130A1 (en) 2019-11-22
JP2020521462A (ja) 2020-07-27
EP3633029A4 (en) 2021-06-09
CN110662834B (zh) 2023-09-12
EP3633029A2 (en) 2020-04-08
KR102460173B1 (ko) 2022-10-31
KR20200001595A (ko) 2020-01-06
AU2018271755A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
AU2018271755A1 (en) Method for culturing natural killer cell, using transformed T cell
MX2022003497A (es) Procesos para producir productos de fermentacion.
EP3638777A4 (en) COMPOSITIONS AND METHODS FOR INCREASING THE EFFICIENCY OF CELL CULTURES FOR FOOD MANUFACTURING
MX2017014089A (es) Método para el cultivo de akkermansia.
MX2020000369A (es) Metodos biologicos para preparar terpenos.
MY169317A (en) Methods for converting lignocellulosic material to useful products
NZ734670A (en) Cells for producing recombinant iduronate-2-sulfatase
EA201390790A1 (ru) Переработка биомассы
EA201491418A1 (ru) Рекомбинантные микроорганизмы и способы их применения
IN2014CN03467A (ko)
MY172080A (en) Microorganisms having putrescine productivity and process for producing putrescine using the same
PH12015500135A1 (en) Processes and systems for the production of fermentation products
HK1226096A1 (zh) 產生藻類細胞培養及藻類生物量、脂質化合物及組合物，以及相關產品的方法
MY182924A (en) Enzyme compositions and uses thereof
MX2015007361A (es) Produccion mediada por la proteina portadora de acilo de los derivados de acidos grasos.
MY193225A (en) Methods for continuous production of products from microorganisms
MX2019009135A (es) Ingenieria metabolica para la produccion microbiana de productos terpenoides.
MX2018013499A (es) Modulacion del metabolismo lipidico para la produccion de proteinas.
IL246525B (en) Pomegranate cell culture and methods for its preparation and use
PH12019500096A1 (en) Leuconostoc mesenteroides cjlm119 strain producing reduced amount of gas, and kimchi production method using same
MX2017012554A (es) Microalgas adaptadas para condiciones de cultivo heterotrofo.
EP4282972A3 (en) Production of branched chain fatty acids and derivatives thereof in recombinant microbial cells
MY188407A (en) Novel lactobacillus sp. microorganisms, and composition for animal feed comprising same
MY181195A (en) Method for producing single cell oil from lignocellulosic materials
PH12014501610A1 (en) Production of coal combustion products for use in cementitious materials

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18805231

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 20197030133

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3062130

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018271755

Country of ref document: AU

Date of ref document: 20180525

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019565241

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2018805231

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2018805231

Country of ref document: EP

Effective date: 20200102